C07C 311/03
Having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms
Official title: having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
C07C311/03 (Having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms) appears on 559 US grants and 454 published applications in this corpus.
Search patents in C07C- Granted patents
- 559
- Published applications
- 454
- Assignees
- 260
- Inventors
- 1,566
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1982 | 1 | 0 |
| 1983 | 3 | 0 |
| 1984 | 1 | 0 |
| 1985 | 2 | 0 |
| 1986 | 1 | 0 |
| 1987 | 1 | 0 |
| 1988 | 0 | 0 |
| 1989 | 2 | 0 |
| 1990 | 5 | 0 |
| 1991 | 5 | 0 |
| 1992 | 9 | 0 |
| 1993 | 6 | 0 |
| 1994 | 10 | 0 |
| 1995 | 12 | 0 |
| 1996 | 21 | 0 |
| 1997 | 32 | 0 |
| 1998 | 22 | 0 |
| 1999 | 17 | 0 |
| 2000 | 22 | 0 |
| 2001 | 30 | 4 |
| 2002 | 36 | 29 |
| 2003 | 40 | 45 |
| 2004 | 24 | 45 |
| 2005 | 21 | 26 |
| 2006 | 20 | 25 |
| 2007 | 16 | 26 |
| 2008 | 14 | 13 |
| 2009 | 16 | 28 |
| 2010 | 15 | 24 |
| 2011 | 18 | 12 |
| 2012 | 13 | 20 |
| 2013 | 11 | 12 |
| 2014 | 10 | 15 |
| 2015 | 16 | 11 |
| 2016 | 12 | 13 |
| 2017 | 9 | 17 |
| 2018 | 11 | 11 |
| 2019 | 13 | 15 |
| 2020 | 7 | 11 |
| 2021 | 11 | 10 |
| 2022 | 8 | 13 |
| 2023 | 3 | 7 |
| 2024 | 5 | 10 |
| 2025 | 7 | 7 |
| 2026 | 1 | 5 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Headgroup lipid compounds and compositions for intracellular delivery of therapeutic agents22 Sep 2026US 12,740,943 B2ModernaTX, Inc.
- Compound useful as toll-like receptor 7 activation inhibitor9 Sep 2025US 12,410,157 B2National Institute of Advanced Industrial Science and Technology
- Compounds and compositions for intracellular delivery of therapeutic agents2 Sep 2025US 12,404,232 B2ModernaTX, Inc.
- Itaconic acid derivatives and uses thereof intreating an inflammatory disease or a disease associated with an undesirable immune response19 Aug 2025US 12,390,437 B2Sitryx Therapeutics Limited
- Modulators of sestrin-GATOR2 interaction and uses thereof5 Aug 2025US 12,378,263 B2Navitor Pharmaceuticals, Inc.
- Sulfonamides With Activity in Acute Kidney Injury and Fibrosis10 Sep 2026US 2026/0263415 A1University of Pittsburgh—Of the Commonwealth System of Higher Education
- Ionizable amine lipids6 Aug 2026US 2026/0225997 A1Intellia Therapeutics, Inc.
- Compounds and compositions for intracellular delivery of therapeutic agents19 Mar 2026US 2026/0078082 A1ModernaTX, Inc.
- Compounds and compositions for intracellular delivery of therapeutic agents12 Mar 2026US 2026/0069549 A1ModernaTX, Inc.
- Modulators of sestrin-gator2 interaction and uses thereof26 Feb 2026US 2026/0055122 A1Navitor Pharmaceuticals, Inc.
Most cited
By later US patents
- Retroviral protease inhibiting compounds159US 5,142,056 AAbbott Laboratories · 1992
- Compounds and compositions for intracellular delivery of therapeutic agents143US 9,868,691 B2ModernaTX, Inc. · 2018
- Retroviral protease inhibiting compounds109US 5,354,866 AAbbott Laboratories · 1994
- Retroviral protease inhibiting compounds94US 5,541,206 AAbbott Laboratories · 1996
- Compounds and compositions for intracellular delivery of therapeutic agents88US 10,857,105 B2MordernaTX, Inc. · 2020